Clinicopathologic Characteristics of Oligometastases from Esophageal Cancer and Long-Term Outcomes of Resection

Ohkura, Yu; Shindoh, Junichi; Ueno, Masaki; Iizuka, Toshiro; Udagawa, Harushi

doi:10.1245/s10434-019-08175-0

Cited by 32 publications

(46 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 In another Japanese study, the outcome was significantly better for the patients who received resection of oligometastases than for those who did not (3-year OS, 64.3% vs 10%). 30 Ghaly et al reported no significant difference in survival according to the local therapies used for isolated recurrent esophageal cancer. 31 Although the definition of oligometastases and the treatment approaches in these studies were different from ours, their experience suggested the importance of local treatment for oligometastatic esophageal cancer.…”

Section: Discussionmentioning

confidence: 98%

Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma

Liu

Zhu

Chen

et al. 2020

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

This study aims to assess the safety and efficacy of stereotactic body radiation therapy (SBRT) for patients with oligometastatic esophageal squamous cell carcinoma (ESCC). Methods and Materials: From April 2015 to December 2018, a prospective, single-arm, phase 2 trial was conducted. The main inclusion criteria were ESCC patients with 3 or fewer metastases and a controlled primary malignancy after radical treatment, with all metastatic lesions amenable to SBRT. The enrolled patients were assigned to SBRT for all metastatic lesions and then received chemotherapy for at least 4 cycles starting from 0 to 15 days after SBRT. The primary endpoint was progression-free survival (PFS). Overall survival, local control, and toxicities were assessed in all patients. The study is listed at clinicaltrials.gov, number NCT 03000816. Results: Thirty-four patients with 40 oligometastatic lesions, including 25 in distant organs and 15 in nonregional lymph nodes, were treated with SBRT. All metastases belonged to genuine oligometastatic disease. Seventeen patients (50.0%) received a median of 4 cycles (interquartile range, 3-6 cycles) of chemotherapy after SBRT. At a median follow-up time of 18.2 months (interquartile range, 11.1-35.0 months), the median PFS time was 13.3 months (95% confidence interval, 10.7-15.9); the 1-and 2-year PFS rates were 55.9% and 33.8%, respectively. The 1-and 2-year overall survival rates were 76.2% and 58.0%, respectively. The 1-and 2-year local control rates were both 92.1%. Grade 3 acute toxicities were observed in only 1 patient. No grade !4 acute adverse events or grade !3 late adverse events due to SBRT occurred in this study.

show abstract

Section: Discussionmentioning

confidence: 98%

Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma

Liu

Zhu

Chen

et al. 2020

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

show abstract

“…Indeed a so-called oligo-recurrence disease, characterized by a single/few detectable metastatic lesions existing after curative therapy for primary lesions, can be considered in this patient ( 13 ). Previous studies have revealed that selected patients with oligo-recurrent diseases may benefit from locally aggressive therapy compared with systemic management alone, especially when surgical resection offers the benefits of diagnostic confirmation of histology and therapeutic excision ( 14 , 15 ). According to the 5th ESO-ESMO international consensus guidelines, 78% of experts supported that limited number and size of metastatic lesions may be potentially amenable for local therapy aimed at achieving a complete remission status ( 16 ).…”

Section: Discussionmentioning

confidence: 99%

Case report: solitary splenic metastasis occurring 19 months after primary treatment for occult breast cancer

et al. 2022

View full text Add to dashboard Cite

Occult breast cancer, commonly presenting with axillary lymphadenopathy, is an extremely rare entity of breast cancer. Metastasis to the spleen as a single site is rarely seen and has been little reported in literature. Herein we described a case of a 60-year-old patient who presented with an asymptomatic solitary splenic mass 19 months after axillary lymph node dissection, regional radiotherapy, and systemic therapy. Laparoscopic splenectomy was performed, and histopathological examination confirmed metastasis from occult breast cancer. Then, the patient was administered with oral vinorelbine and dual-targeted treatment. With over 10 months of follow-up, there is no evidence of recurrence or metastasis of malignancy. To our knowledge, this study reports the first case of solitary splenic metastasis from occult breast cancer and highlights the importance of considering splenic metastasis as the only site of recurrence during follow-up of primary cancer, regardless of its rarity. If possible, splenectomy may be a therapeutic strategy.

show abstract

“…Ohkura et al ( 10 ) reported that the overall survival rate was significantly better for patients who underwent resection of oligometastasis from esophageal cancer than for those who did not (3-year survival rates, 64.3 vs. 10%, respectively; 5-year survival rates, 55.6 vs. 10%, respectively). Alternatively, SBRT is a radiation technique that enables irradiation of a small target in the body using a high dose.…”

Section: Discussionmentioning

confidence: 99%

Postoperative solitary liver metastasis from esophageal squamous cell carcinoma achieving a clinical complete response to chemotherapy with cisplatin and 5‑fluorouracil followed by stereotactic body radiotherapy: A case report

et al. 2021

View full text Add to dashboard Cite

Treatment strategies for distant organ metastasis have changed markedly since the concept of oligometastasis was introduced. The perception that distant organ metastasis is a systemic disease and not eligible for local therapy is now a thing of the past. Therefore, the present report details a case of postoperative solitary liver metastasis from esophageal squamous cell carcinoma (ESCC), which achieved a clinical complete response to chemotherapy with cisplatin and 5-fluorouracil (5-FU) followed by stereotactic body radiotherapy (SBRT). A 76-year-old male patient underwent esophagectomy for lower thoracic ESCC. At 7 months after surgery, abdominal CT revealed a solitary hypovascular mass, 28 mm in size, in segment 7 of the liver. After three courses of chemotherapy with cisplatin and 5-FU, abdominal CT revealed that the liver mass had shrunk to 7 mm in size. SBRT was then administered with a 6 MV X-ray beam generated by a linear accelerator. A total dose of 50 Gy was given in 5 fractions of 10 Gy to the liver mass. At 1 month after SBRT, abdominal CT revealed that the liver mass had disappeared. The patient received no further adjuvant chemotherapy and had no recurrence at 18 months after diagnosis of liver metastasis and 13 months after SBRT.

show abstract

Clinicopathologic Characteristics of Oligometastases from Esophageal Cancer and Long-Term Outcomes of Resection

Cited by 32 publications

References 21 publications

Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma

Phase 2 Study of Stereotactic Body Radiation Therapy for Patients with Oligometastatic Esophageal Squamous Cell Carcinoma

Case report: solitary splenic metastasis occurring 19 months after primary treatment for occult breast cancer

Postoperative solitary liver metastasis from esophageal squamous cell carcinoma achieving a clinical complete response to chemotherapy with cisplatin and 5‑fluorouracil followed by stereotactic body radiotherapy: A case report

Contact Info

Product

Resources

About